Repository logo
 

Genome-wide CRISPR/Cas9 deletion screen defines mitochondrial gene essentiality and identifies routes for tumour cell viability in hypoxia.

Accepted version
Peer-reviewed

Type

Article

Change log

Authors

Esposito, Cinzia 
Morgan, Rachel E 
Price, Stacey 
Young, Jamie 

Abstract

Mitochondria are typically essential for the viability of eukaryotic cells, and utilize oxygen and nutrients (e.g. glucose) to perform key metabolic functions that maintain energetic homeostasis and support proliferation. Here we provide a comprehensive functional annotation of mitochondrial genes that are essential for the viability of a large panel (625) of tumour cell lines. We perform genome-wide CRISPR/Cas9 deletion screening in normoxia-glucose, hypoxia-glucose and normoxia-galactose conditions, and identify both unique and overlapping genes whose loss influences tumour cell viability under these different metabolic conditions. We discover that loss of certain oxidative phosphorylation (OXPHOS) genes (e.g. SDHC) improves tumour cell growth in hypoxia-glucose, but reduces growth in normoxia, indicating a metabolic switch in OXPHOS gene function. Moreover, compared to normoxia-glucose, loss of genes involved in energy-consuming processes that are energetically demanding, such as translation and actin polymerization, improve cell viability under both hypoxia-glucose and normoxia-galactose. Collectively, our study defines mitochondrial gene essentiality in tumour cells, highlighting that essentiality is dependent on the metabolic environment, and identifies routes for regulating tumour cell viability in hypoxia.

Description

Keywords

CRISPR-Cas Systems, Cell Proliferation, Genes, Mitochondrial, Genome, Mitochondrial, Glycolysis, Humans, Hypoxia, Mitochondria, Neoplasms, Oxidative Phosphorylation, Tumor Cells, Cultured

Journal Title

Commun Biol

Conference Name

Journal ISSN

2399-3642
2399-3642

Volume Title

4

Publisher

Springer Science and Business Media LLC
Sponsorship
Medical Research Council (MR/K002201/2)
Cancer Research UK (19442)
ERC, Addenbrookes Charitable Trust